ProMIS Neurosciences Inc (PMN)
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint inAlzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint inAlzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical